MBX Biosciences, Inc.
mbxbio.comWhat Do They Do?
Develops precision peptide therapies for endocrine and metabolic disorders, including treatments for hypoparathyroidism, obesity and post-bariatric hypoglycemia.
10-K for FY2025, filed Mar 12, 2026We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide…View ↗
Canvuparatide: Our lead product candidate, canvuparatide (MBX 2109), is a parathyroid hormone ("PTH") peptide prodrug that is designed as a…View ↗
Obesity portfolio: Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent "PEP™ glucagon-like…View ↗
Imapextide: Our program, imapextide (MBX 1416), is designed to be a long-acting GLP-1 receptor antagonist as a potential therapy for…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 12, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$37.1MView ↗
- ▲ +91% (Loss)
- vs −$19.4M in Q2 FY2025
-
Aug 27, 2026
The first patient was dosed in the canvuparatide Phase 3 trial.
The trial evaluates once-weekly canvuparatide in adults with chronic hypoparathyroidism.
Sources
8-K, filed Aug 27, 2026
On August 27, 2026, the Company announced the dosing of the first patient in its pivotal Phase 3 oPTimize clinical trial evaluating…View ↗
-
Jul 13, 2026
Steve Hoerter became CEO, succeeding Kent Hawryluk.
Hoerter was appointed President and CEO effective July 13, 2026.
Sources
8-K, filed Jul 13, 2026
Kent P. Hawryluk will be stepping away from his role as the Company’s Chief Executive Officer and end his services as a member of the Board…View ↗
Who Do They Compete With?
Competes with Ascendis Pharma, AstraZeneca, Extend Biosciences, Septerna, BridgeBio/Calcilytix, Eli Lilly and, Novo Nordisk, Amgen, Roche, Viking Therapeutics, Zealand Pharma, Amylyx Pharmaceuticals, Vogenx, and Recordati
10-K for FY2025, filed Mar 12, 2026Ascendis Pharma has Yorvipath approved in the United States, EU, Australia, and Japan for the treatment of HP in adults.View ↗
Loading...
